Zelluna ASA — Earnings Release 2019

Nov 9, 2019

Ultimovacs ASA – LONG TERM RESULTS FROM UV1 CLINICAL STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Ultimovacs ASA – LONG TERM RESULTS FROM UV1 CLINICAL STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Oslo,9 November 2019: Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), a pharmaceutical company developing novel immunotherapies against cancer, presents long-term results from a clinical study with UV1 in patients with Non-Small Cell Lung Cancer (“NSCLC”) during a poster session at the Society for Immunotherapy of Cancer’s 34th Annual Meeting (SITC 2019) today.

The data is from a UV1 dose finding study in previously treated patients with advanced stage (III/IV) NSCLC. Eighteen patients were enrolled, with six patients in each of three different UV1 dose groups (100, 300 and 700µg), with GM-CSF as adjuvant. Main endpoints were safety, immune response against UV1 peptides and efficacy including long-term survival.

The main results are:

• UV1 was well tolerated without any severe safety events

• UV1 induced a specific immune response in 67% of the patients

• Median overall survival was 28.2 months

• Four years overall survival was 39% (7 of 18 patients alive)

• All results favor the highest UV1 dose (700µg) for this patient population. In the 700µg dose group, 5 of 6 patients were still alive 4 years after treatment start

• None of the long-term survivors have received any other immunotherapy during the follow-up time

Ultimovacs has completed three phase I studies with UV1; in prostate cancer, malignant melanoma and NSCLC. These three studies have shown clinical outcomes that Ultimovacs views as a strong basis for further clinical development of UV1. The NSCLC long-term results presented at SITC today further strengthen this conclusion.

Detailed results from the study will be presented at SITC 2019 by Professor Emeritus Gustav Gaudernack. The poster (ID: P342) title is “Long Term Outcome of a Phase I Study with UV1, a Second-Generation Telomerase based Vaccine in Patients with Advanced Non-Small Cell Lung Cancer”. The poster is available at www.ultimovacs.com

UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immunotherapy which require an ongoing T cell response for their mode of action.

For further information, please see www.ultimovacs.com or contact:

Øyvind Kongstun Arnesen, CEO

oeyvind.arnesen@ultimovacs.com, +47 469 33 810

Hans Vassgård Eid, CFO

hans.eid@ultimovacs.com, +47 469 19 822